ORPHA:1446
Ring chromosome 22 syndrome
Also known as: Ring 22 · Ring chromosome 22 · r(22) syndrome
Publications
953
Trials
0
Interventional, condition-specific
Researchers
1,431
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
A rare anomaly characterized by variable clinical features, most commonly including global , , growth retardation with microcephaly, with severe speech delay, or abnormal EEG, autistic spectrum disorder and other behavioral characteristics.
How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0015438
- MeSH:C536795
- UMLS:C0265492
Additional Mondo synonyms (2)
Chromosome 22 Ring · Ring chromosome type 22
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
Research-stage checklist from open sources (GenCC, literature, Monarch when enriched, ClinicalTrials.gov). Not a prognosis or care recommendation.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
953 matched papers (474 in last 10 years) Source
- Phenotype characterisedPresent
33 HPO annotations (e.g. Azoospermia; Long face; Epicanthus) Source
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialNot found
No matched interventional trial under our ClinicalTrials.gov rules
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
33
Associated phenotypes · MONDO:0015438
- Azoospermia
- Long face
- Epicanthus
- Full cheeks
- Pointed chin
Showing 5 of 33 — open Monarch for the full list.
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
No drugs or clinical candidates returned for this Mondo ID on Open Targets.
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
953
953 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
953 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
474 in the last 10 years · low confidence
Phrase hits: 953 · MeSH hits: 0
Who's working on it?
1,431
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Kolevzon A9 papers · 2025
Seaver Autism Center for Research and Treatment, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1230, New York, NY, 10029, USA. alexander.kolevzon@mssm.edu.
Papers in Europe PMC - 02Buxbaum JD8 papers · 2025
Seaver Autism Center for Research and Treatment, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1230, New York, NY, 10029, USA.
Papers in Europe PMC - 03Berry-Kravis E6 papers · 2026
Department of Pediatrics, Rush University Medical Center, Chicago, IL.
Papers in Europe PMC - 04Betancur C6 papers · 2024
Sorbonne Université, INSERM, CNRS, Neuroscience Paris Seine, Institut de Biologie Paris Seine, Paris 75005, France.
Papers in Europe PMC - 05Li J6 papers · 2026
Hoffmann Institute of Advanced Materials, Shenzhen Polytechnic University 7098 Liuxian Blvd, Nanshan District Shenzhen 518055 People's Republic of China lijingbai@szpu.edu.cn.
Papers in Europe PMC - 06Levy T5 papers · 2025
Seaver Autism Center, Icahn School of Medicine at Mount Sinai, New York, NY, United States.
Papers in Europe PMC - 07Thurm A5 papers · 2025
Neurodevelopmental and Behavioral Phenotyping Service, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland 20814, USA.
Papers in Europe PMC - 08Zhang Y5 papers · 2025
Center for Neural Science, New York University, New York, NY, United States.
Papers in Europe PMC - 09Bernstein JA4 papers · 2025
Department of Pediatrics, Stanford University, Stanford, CA, 94304, USA.
Papers in Europe PMC - 10Halpern D4 papers · 2022
Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present).
Data as of 11 September 2026 · last trial check 11 September 2026
No matched interventional trials. This is true for 77.2% of diseases in the trials denominator (5501 of 7126). Here are the researchers publishing on it.
low confidence · 38.6th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
See who's working on it — people publishing on this disease are often the practical next contact when no trial is listed.
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 40 · after dedupe 40 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 40 · dropped 0 · fetched 2026-07-29
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Uncertain / not reviewed (40)
- isrctn·ISRCTN11399176·Recruiting·Safer labour induction with the EBLIA balloon
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN17000942·Recruiting·The international ‘100 DU’ study
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN18283468·No longer recruiting·A clinical trial to learn more about the absorption of radiolabeled drug LXE408, how the body breaks it down, and how quickly the body gets rid of it in healthy men
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN33793580·Recruiting·18F-LW223: A new tool for detecting inflammation in the body
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN16645843·Recruiting·Efficacy of CliMACT, a digital training for mental health promotion in youth with climate change-related distress
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN12166286·No longer recruiting·A study in healthy adults to compare the bioavailability of EPA + DHA from two microalgal sources to one fish source and placebo
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN17575891·No longer recruiting·The use of digital media in patient education for the secondary prevention of coronary heart disease
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN14632228·Recruiting·Research study for people who have cerebral small vessel disease (cSVD, damaged small blood vessels in the brain) and a stroke, which may lead to impaired memory and thinking and then dementia
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN10890272·Recruiting·Pelvic floor muscle exercises plus pessary for treatment of prolapse versus pelvic floor muscle exercises alone
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN99912974·Recruiting·Phase-locked brain stimulation for people with Parkinson's disease
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN17198496·No longer recruiting·Effects of a liquid blend containing kava and kratom in healthy adults
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN29801527·No longer recruiting·A study to characterize nicotine delivery of the JUUL2 electronic nicotine delivery system in adults as compared to a commercially available e-cigarette and combustible cigarette
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN15140257·Stopped·Effect of Icosapent ethyl on inflammation in the vessel wall assessed by the Fat Attenuation Index Score (IRIS-FAI)
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN34837836·No longer recruiting·A study to characterize nicotine delivery of the JUUL2 electronic nicotine delivery system as compared to a commercially available e-cigarette and combustible cigarette
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN16176441·No longer recruiting·A clinical study to evaluate the contents of exhaled breath after use of the JUUL2 electronic nicotine delivery system and conventional cigarettes
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN70584524·No longer recruiting·How taking magnesium affects sleep and health in adults with poor sleep quality: a study with randomized blinding and placebo control
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN27514808·No longer recruiting·A study investigating the effectiveness, safety and quality of life in participants with age related visual impairment (macular degeneration) who have switched to faricimab, under real world conditions in Germany
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN60504239·No longer recruiting·Study on nicotine uptake in smokers using electronic nicotine delivery systems compared to combustible cigarette
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN88955347·No longer recruiting·Studies on the effects of light on human neuroendocrine physiology and cognition
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN15259909·No longer recruiting·Phase I psilocybin safety trial
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN16482972·No longer recruiting·A Phase I, non-randomized, open-label, crossover study designed to evaluate the pharmacokinetic profile of iptacopan (LNP023) following single-dose administration of iptacopan modified-release formulations in comparison to a reference capsule formulation in healthy participants
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN51932144·No longer recruiting·The effects of Muno-IgYTM on immune function in healthy adult volunteers
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN17779071·No longer recruiting·Efficacy and safety assessment of T4032 (unpreserved bimatoprost 0.01%) versus Lumigan® 0.01% in ocular hypertensive or glaucomatous patients
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN17518945·No longer recruiting·Trial of sertraline to prevent post-traumatic brain injury depression
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN15101017·No longer recruiting·Investigating the effectiveness of deep brain stimulation in improving reaching movements in people with Parkinson's disease
skipped — LLM skipped (--skip-llm)
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Ring chromosome 22 syndrome — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Ring chromosome 22 syndrome" OR "Ring 22" OR "Ring chromosome 22" OR "r(22) syndrome" OR "Chromosome 22 Ring" OR "Ring chromosome type 22"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Ring chromosome 22 syndrome" OR "Ring 22" OR "Ring chromosome 22" OR "r(22) syndrome" OR "Chromosome 22 Ring" OR "Ring chromosome type 22"
Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
- Publication count (953) is implausibly high for prevalence class "<1 / 1 000 000" — treat as possible over-matching, not a measure of research intensity
Ingested 2026-07-26T17:23:33.233Z
